Physician profile
Jeffrey G Wright
NPI 1235179177
$11,437.74
in general payments reported to CMS, 2019-2025
53 companies · $1,150 in 2025
The $1,150 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,952 · 2020: $970 · 2021: $3,015 · 2022: $675 · 2023: $1,129 · 2024: $1,547 · 2025: $1,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,710 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,709.85 |
| Education | $116.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,580.15 | 2019-2025 | Airsupra, Breztri, Andexxa |
| Actelion Pharmaceuticals US, INC. | $1,281.01 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $941.55 | 2019-2025 | Ofev, Jascayd |
| Pulmonx Corporation | $860.74 | 2019-2020 | |
| Glaxosmithkline, LLC. | $787.24 | 2019-2025 | Nucala, Trelegy Ellipta |
| United Therapeutics Corporation | $547.11 | 2019-2025 | Tyvaso, Orenitram, Tyvaso |
| Insmed, INC. | $486.00 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $351.50 | 2019-2025 | |
| Genentech USA, INC. | $341.63 | 2019-2023 | Xolair |
| Abbott Laboratories | $303.44 | 2024-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Harmony Biosciences LLC | $271.35 | 2021-2025 | Wakix |
| Novartis Pharmaceuticals Corporation | $196.46 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $181.23 | 2019-2024 | Keytruda, Zerbaxa, Winrevair |
| Grifols USA, LLC | $149.20 | 2019-2023 | Prolastin-C Liquid |
| Ani Pharmaceuticals, INC. | $147.97 | 2025 | Purified Cortrophin Gel |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.